Stockscreener 앱 받기
13.56
1.65%
0.22
전일 마감가:
$13.34
열려 있는:
$13.48
하루 거래량:
182.79K
Relative Volume:
0.38
시가총액:
$936.26M
수익:
$26.98M
순이익/손실:
$-180.66M
주가수익비율:
-2.6433
EPS:
-5.13
순현금흐름:
$-63.56M
1주 성능:
-8.44%
1개월 성능:
-7.63%
6개월 성능:
-39.27%
1년 성능:
-23.61%
1일 변동 폭
$13.38
$13.90
1주일 범위
$13.20
$15.30
52주 변동 폭
$12.17
$28.67
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
명칭
Bicycle Therapeutics Plc Adr
전화
011441223261503
주소
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
BCYC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
13.56 | 936.26M | 26.98M | -180.66M | -63.56M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Equal-Weight |
| 2024-09-06 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-07 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | 개시 | Cowen | Outperform |
| 2022-07-28 | 개시 | Barclays | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-04-13 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-02-14 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | SVB Leerink | Outperform |
| 2021-12-09 | 개시 | Needham | Buy |
| 2021-09-30 | 개시 | B. Riley Securities | Buy |
| 2021-04-20 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-06-12 | 개시 | Oppenheimer | Outperform |
| 2020-04-17 | 개시 | H.C. Wainwright | Buy |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-09-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-06-17 | 개시 | Canaccord Genuity | Buy |
| 2019-06-17 | 개시 | Goldman | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
| 2019-06-17 | 개시 | Piper Jaffray | Overweight |
모두보기
Bicycle Therapeutics Plc Adr 주식(BCYC)의 최신 뉴스
Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com India
Bicycle Therapeutics reports promising cancer drug trial results - Investing.com India
Bicycle therapeutics CDO Santiago Arroyo sells shares worth $69,646 - Investing.com India
Bicycle Therapeutics CFO Alethia Young sells shares totaling $19,655 - Investing.com
Bicycle Therapeutics exec sells $30k in shares - Investing.com
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares By Investing.com - Investing.com South Africa
Bicycle Therapeutics CTO sells shares worth $60,119 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares - Investing.com
Bicycle Therapeutics CEO Lee sells shares worth $172,952 By Investing.com - Investing.com South Africa
Bicycle Therapeutics CEO Lee sells shares worth $172,952 - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock outlook amid clinical trials and cash strength - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data - Investing.com
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - Yahoo Finance
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study - Yahoo Finance
Pharmacovigilance and Drug Safety Software Market Size to Reach USD 371.88 Million by 2032, Growing at a 6.76% CAGR – SNS Insider - Yahoo Finance
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study - Yahoo Finance
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potential - Investing.com India
Bicycle Therapeutics' chief accounting officer sells shares worth $157,113 - Investing.com
Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform - Investing.com India
Bicycle Therapeutics retains stock target and Buy rating on promising data - Investing.com
Bicycle Therapeutics spotlights cancer treatment targets - Investing.com
Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - MSN
A company insider recently sold 3,212 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You also Consider to Sale? – Knox Daily - Knox Daily
BCYC’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Keeping an Eye on Bicycle Therapeutics Plc ADR (BCYC) After Insider Trading Activity - Knox Daily
Bicycle Therapeutics Plc ADR (BCYC)’s stock price range in the last year - US Post News
Bicycle therapeutics executive sells shares worth over $21k - Investing.com India
Bicycle therapeutics executive sells shares to cover tax obligations - Investing.com India
Bicycle therapeutics COO sells shares worth over $21k - Investing.com India
Bicycle therapeutics CEO sells shares worth over $71k - Investing.com
Bicycle therapeutics CTO sells shares worth over $21k - Investing.com
Bicycle therapeutics executive sells shares worth over $5,000 - Investing.com
CHIEF PROD & SUPPLY CHAIN OFF Hannay Michael Charles Ferguso sale 246 shares of Bicycle Therapeutics Plc ADR [BCYC] – Knox Daily - Knox Daily
Bicycle Therapeutics Plc ADR (BCYC)’s stock chart: A technical perspective - US Post News
Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 22.56 - The Dwinnex
Bayer Reports Positive Safety Data on Parkinson's Disease Drug - Yahoo Finance
Wall Street SWOT: Bicycle Therapeutics stock rides high on cancer drug promise - Investing.com
A company insider recently sold 246 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You Sale? - Knox Daily
Nothing is Better Than Bicycle Therapeutics Plc ADR (BCYC) stock at the moment - SETE News
RBC Capital Mkts initates Bicycle Therapeutics Plc ADR (BCYC) stock to an Outperform - Knox Daily
Metric Analysis: Bicycle Therapeutics Plc ADR (BCYC)’s Key Ratios in the Limelight - The Dwinnex
Bicycle Therapeutics Plc ADR: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Are Bicycle Therapeutics Plc ADR (BCYC) shares a good deal now? - US Post News
Hain Celestial Group Inc [HAIN] Investment Guide: What You Need to Know - Knox Daily
Bicycle Therapeutics stock maintains Buy rating post-ESMO data By Investing.com - Investing.com UK
Bicycle Therapeutics Plc Adr (BCYC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):